One of the rising penny stocks from the healthcare field OpGen (NASDAQ: OPGN) surges more than 60% in premarket as Curetis testing kit for SARS-COV-2 receives certification from the EU. Thus, the revenue may pop soon along with earnings, eventually, making the stock soar higher than $10 or $20.
Its EPS soon may lose the ‘minus’ sign in Q3 and Q4 financial results. It is perhaps the right time to buy OPGN for $1000 at least as the earnings seem to increase.
Late jumpers may see that Q4 earnings show good results and together with long term risk-averse investors they will buy OPGN in bulks. This is just an assumption of an average trader. The situation may change against the stock anytime.
Finance and Tech Contributor